Epilepsy and preconception — MCCQE Part 1 MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Arrange a specialist-led preconception change from valproate to a safer effective antiseizure medicine
Valproate carries substantial fetal malformation and neurodevelopmental risk, so the priority is a preconception epilepsy-specialist review and, when clinically feasible, a planned transition to a lower-risk effective medicine before conception. Valproate must not be stopped abruptly: uncontrolled seizures also endanger the patient and fetus, and the Canadian guideline explicitly allows time for taper and overlap. Folic acid is additional risk reduction, not a substitute for medication review. The cited Canadian regimen for women taking antiseizure medicines is 1 mg/day (1,000 micrograms/day) beginning 3 months before conception through the first trimester, then 0.4 mg/day (400 micrograms/day); the stored statement that all such patients require 5 mg/day was not supported by this guidance.
Reference: Public Health Agency of Canada, Family-Centred Maternity and Newborn Care: Chapter 2, section 7.4 Seizure Disorders: https://www.canada.ca/en/public-health/services/publications/healthy-living/maternity-newborn-care-guidelines-chapter-2.html ; Health Canada, Health Product InfoWatch — valproate products and pregnancy: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/medeff/bulletin/hpiw-ivps_2017-04-eng.pdf